Vol.

No.

September 27, 2024Sep 27, 2024

DOWNLOAD THE PDF

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors Problem: “Breast density is in the eye of the mammographer”

Cover Story

Regulatory News

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors

Problem: “Breast density is in the eye of the mammographer”

By Claire Marie Porter

While breast cancer experts are anything but clear on what the words “dense breasts” signify in the clinic, or for that matter, in the English language, FDA appears to be less perplexed.

Regulatory News

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

By Jacquelyn Cobb

PubMed’s failure to display all papers by authors who publish under multiple names “mistreats women,” lawsuit contends

By Jacquelyn Cobb

Cancer History Project Guest Editorial

How First Lady Betty Ford and surgeon Bernie Fisher revolutionized America’s attitude toward breast cancer

By Stacy Wentworth

Free In the Archives

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

In Brief

Sanya Springfield named NCI acting deputy director for health equity and inclusion

Judith Hopkins receives Harry Hynes Award

UMich Rogel Cancer Center receives $25M from Weiser Charitable Foundation

Cure4Cancer initiative proposes solutions for unlocking $80B oncology R&D investment and reducing global cancer disparities

ACS CAN supports legislation to make permanent ACA enhanced tax credits

MD Anderson launches academic journal Advances in Cancer Education & Quality Improvement

Anthony Stack joins Fox Chase as assistant professor in bone marrow transplant and cellular therapies

Hilario Yankey joins Fox Chase as assistant professor in radiation oncology

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Clinical Roundup

Vulnerable patients have a decreased mortality risk when treated at CoC-accredited hospitals, ACS study says

UCLA investigators develop collection of sarcoma patient-derived organoids for personalized cancer treatments

Drugs & Targets

FDA approves Sarclisa + VRd for MM not eligible for transplant

FDA approves Tagrisso for stage 3 EGFR-mutated NSCLC

EC approves Vyloy + chemo for advanced gastric and GEJ cancers

EU CHMP gives positive opinion to Keytruda for two types of gynecologic cancers

Bayer submits sNDA to FDA for expanded indication for Nubeqa for treatment of mHSPC

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues